ST步森(002569.SZ):擬註銷子公司南昌市軒琪科技有限公司
格隆匯11月17日丨ST步森(002569.SZ)公佈,為進一步整合現有資源配置,優化內部管理結構,降低管理成本,提高運營效率,根據公司的發展戰略和經營規劃,擬註銷公司子公司南昌市軒琪科技有限公司,並授權經營管理層依法辦理相關清算和註銷等相關工作。
公司原計劃以子公司南昌市軒琪科技有限公司收購廣東信匯電子商務有限公司60.4%股權,結合廣東信匯股權過户進展情況及市場因素變化,綜合考慮之後公司決定終止該收購事項,並於2021年7月20日發佈了公吿《關於終止收購廣東信匯電子商務有限公司60.4%股權的公吿》。子公司南昌市軒琪科技有限公司目前已無實際經營業務,所以註銷不影響公司整理髮展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.